ArticleScientific reports2022

No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance.

Karolina Cyll et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.